Recombinant mumps virus vaccine
AssigneesUniversity of Georgia Research Foundation, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBiao He, Steven A. Rubin
Life of this patent
Estimating the term…
Abstract
The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/US/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to rMuVIowa/US/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuVΔSH) and/or incapable of expressing the V protein (rMuVΔV).
Claims17
A live-attenuated recombinant mumps virus (rMuV) comprising one or more mutations to the V/I/P gene abrogating expression of the V protein compared to a parent mumps virus from which the live-attenuated rMuV is mutated.
An isolated nucleotide sequence comprising the cDNA sequence encoding a full length RNA genome of an live-attenuated mumps virus that grows to a titer in Vero cells similar to the titer of wild type virus in Vero cells, wherein the cDNA sequence encoding the full length RNA genome of the mumps virus comprises one or more mutations to the V/I/P gene abrogating expression of the V protein.
Dependencies are inferred from the claim text.